Roche Holding AG (RHHBY)
Sector: Drug Manufacturers - General
Industry: Drug Manufacturers - General
Roche Holding AG
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 58.32 | 59.61 | 58.20 | 59.37 | 1,096,381 |
| Nov 5, 2026 | 59.76 | 60.40 | 59.33 | 59.45 | 981,495 |
| Nov 4, 2026 | 60.28 | 61.04 | 59.88 | 60.94 | 1,118,542 |
| Nov 3, 2026 | 60.43 | 60.58 | 59.13 | 59.18 | 1,132,298 |
| Nov 2, 2026 | 60.48 | 60.76 | 60.22 | 60.67 | 2,091,787 |
| Oct 30, 2026 | 61.10 | 61.44 | 60.75 | 61.27 | 1,523,441 |
| Oct 29, 2026 | 60.56 | 61.03 | 60.51 | 60.77 | 1,148,667 |
| Oct 28, 2026 | 59.46 | 60.28 | 59.39 | 60.22 | 1,274,744 |
| Oct 27, 2026 | 59.42 | 60.37 | 59.41 | 60.37 | 2,544,554 |
| Oct 26, 2026 | 59.82 | 60.15 | 59.70 | 59.98 | 3,624,604 |
| Oct 23, 2026 | 59.53 | 61.49 | 59.00 | 61.17 | 2,699,576 |
| Oct 22, 2026 | 58.65 | 59.83 | 58.41 | 59.62 | 979,287 |
| Oct 21, 2026 | 59.14 | 59.49 | 58.83 | 59.11 | 1,353,176 |
| Oct 20, 2026 | 58.58 | 59.21 | 58.52 | 59.11 | 1,565,161 |
| Oct 19, 2026 | 57.37 | 57.60 | 57.14 | 57.14 | 1,027,264 |
| Oct 16, 2026 | 57.15 | 57.47 | 57.02 | 57.14 | 2,713,205 |
| Oct 15, 2026 | 56.68 | 57.22 | 56.62 | 56.78 | 1,501,296 |
| Oct 14, 2026 | 54.58 | 55.75 | 54.56 | 55.69 | 650,002 |
| Oct 13, 2026 | 54.55 | 54.57 | 53.71 | 53.77 | 893,702 |
| Oct 12, 2026 | 53.99 | 54.22 | 53.84 | 54.10 | 1,783,050 |
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors.
The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium.
Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus.
Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
based on 6.42B shares outstanding
CH30d Avg
1.59M
60d Avg
1.50M
90d Avg
1.81M